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Association of Polygenic Liability for Autism
With Face-Sensitive Cortical Responses From Infancy
Autism is a heritable condition affecting 1% of people world-
wide. Despite a pressing need for early intervention, the de-
velopmental paths through which genetic variants are asso-
ciated with emerging behavioral symptoms in infancy remain
opaque. The latency of the
N170 event-related potential
response to faces is replica-
bly altered in individuals with autism1 and has potential as a
stratification biomarker for prognostic social functioning.2 The
N170 precursor (N290) to faces vs nonfaces is also altered prior
to symptom emergence in infants subsequently diagnosed with
autism.3 These early differences in brain processing repre-
sent a plausible developmental mechanism linking genetic li-
ability and behavioral autism symptoms. We investigated
whether N290 latency to faces vs nonfaces is associated with
autism polygenic scores and cross-disorder polygenic scores
in infants with and without a family history of autism.
Methods | In this cohort study, 104 infants with and without a
family history of autism provided DNA and participated in an
electroencephalography (EEG) task3 presenting face and
nonface images as part of a longitudinal prospective study (the
British Autism Study of Infant Siblings [BASIS]). Diagnostic as-
sessments at age 3 years determined whether infants with a
family history of autism were diagnosed with autism, showed
typical development, or showed other signs of atypical devel-
opment (Table). Ethical approval was obtained from the Health
Research Authority of the English National Health Service. Par-
ents gave written informed consent.
Infants viewed face or nonface (scrambled pixels of the
face) images while brain electrical activity was measured
continuously with a 128-channel Hydrocel Sensor Net Sys-
tem (Electrical Geodesics Inc). N290 latency was extracted
for each condition (220 to 319 milliseconds; more than 10
good-quality EEG trials; mean of 19 occipitotemporal elec-
trodes), and the difference in N290 latency between face
and nonface stimuli was computed (face-nonface [F-N]
N290 latency).
Genome-wide genotype data were obtained from saliva
and buccal cheek-swab DNA.4 Standardized polygenic scores
were calculated using PRSice-2 software in R version 3.6.3 (The
R Foundation) for 234 unrelated infants of European ances-
try, assigned by the investigators based on principal compo-
nent analysis on a combined sample of infants’ and Hapmap3
genotypes. Autism polygenic scores and cross-disorder poly-
genic scores were generated using the Autism5 and
Cross-Disorder6 European-based genome-wide association
studies (GWAS) at a range of P value thresholds (.001 < thresh-
old P ≤ 1). Linkage disequilibrium estimation for clumping
(r2 < 0.1; 250-kilobase distance from index variant) was based









follow-up No FH FH-TD FH-Other FH-Aut P value η2a
Total, No. 104 3 22 45 20 14 NA NA NA





















































Mullen Scales of Early Learning
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.009 <.001 η2[H] =
0.19g
Abbreviations: FH-Aut, infants with a family history of autism and a later
diagnosis of autism; FH-Other, infants with a family history of autism and with
neurodevelopmental difficulties at age 3 years who did not meet criteria for a
clinical diagnosis of autism; FH-TD, infants with a family history of autism and
typical development at age 3 years; F-N N290 latency, N290 latency difference
between the face and the nonface conditions; No FH, infants with no family
history of autism; PGS, polygenic score.
a η2 Indicates eta-squared as a measure of the analysis of variance effect size.
b Significant differences based on Tukey honest significant difference
post hoc test.
c Significant differences based on Tukey honest significant difference post hoc
test.
d Significant differences based on Dunn post hoc test.
e Significant differences based on Dunn post hoc test.
f Significant differences based on Dunn post hoc test.
g η2[H], eta squared based on the H statistic obtained in the Kruskal-Wallis test
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on the 1000 Genomes Project reference panel. Five ancestry
principal components were included as covariates.
RegressionanalysestestedtheassociationbetweenF-NN290
latencyandautismpolygenicscoresandcross-disorderpolygenic
scores at the GWAS P value thresholds that explained the high-
est variance (Nagelkerke R2) in infants with autism and a family
history of autism and those with atypical development (whether
autismorother).Modelfit improvementwastestedusingχ2 when
adding autism polygenic scores to the logistic model that tested
the association of F-N N290 latency with autism. Tests were
2-tailed and significance was set at P < .05. Details on diagnos-
tic assessment, EEG, and genetic data preprocessing are available
in the eMethods in the Supplement and online at https://github.
com/annagui/PGS_EEG.
Results | Of 104 infants included in this study, 53 were female
(51.0%). The mean (SD) age was 8.3 (1.2) months. As previously
reported,2 infantslaterdiagnosedwithautismshoweddiminished
differentiation between N290 latency to face and nonface stimuli
relativetoinfantswithoutafamilyhistoryofautism(Table;Figure,
A). Higher autism polygenic scores (threshold P = .01; number of
singlenucleotidevariants = 4806;NagelkerkeR2 = 0.054;P = .01)
(Figure, B) was associated with shorter N290 latency to face vs
nonface stimuli (β = −3.89; SE = 1.94; P = .047) (Figure, C). Cross-
disorder polygenic score (threshold P = .50; number of single
nucleotide variants = 59 669; Nagelkerke R2 = 0.015; P = .15) was
even more strongly associated with F-N N290 latency (β = −5.05;
SE = 1.81; P = .006) (Figure, D). Testing the association between
these precursors and autism (dependent variable), the model fit
significantlyimprovedwhenaddingpolygenicscorestoF-NN290
latency as an independent variable (McFadden R2 = 0.121;
P = .008).
Discussion | Altered cortical responses to social vs nonsocial
stimuli in infancy may be one brain processing pathway
through which genetic liability leads to behavioral autism
















































Association of face/nonface N290 latency with autism
polygenic score
C
–2 0 2 4
Autism polygenic score (threshold P=.01)
–2 0 2 4
Cross-disorder polygenic score (threshold P=.50)
Autism polygenic score density distributionB















































Other signs of atypical development and FH
Typical development and FH
Shaded area indicates standard
errors; error bars, standard error of
the mean. FH indicates a family
history of autism.
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symptoms and may suggest a suitable target for early identi-
fication. This study has limitations. The relatively small size
and composition of the sample somewhat limit the general-
izability of findings. Future studies should leverage larger
GWAS and population infant samples, including those of
non-European ancestry.
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